CommercialCoverageHigh impact
Orthopedic Applications of Stem Cell Therapy (Including Allografts and Bone Substitutes Used with Autologous Bone Marrow)
Blue Cross & Blue Shield of Mississippi·MS · Orthopedics, General Surgery, Neurosurgery +3 more·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS MS has updated their policy declaring all mesenchymal stem cell therapy, allograft bone products with viable stem cells, and bone graft substitutes requiring autologous blood/bone marrow as investigational and non-covered for orthopedic applications. This policy clarifies that these treatments will not be reimbursed.
Action Required
Immediately: Billing team must identify all claims for stem cell therapy, DBM with stem cells (AlloStem, Osteocel Plus, Trinity Evolution Matrix, Trinity Elite), and bone substitutes requiring autologous marrow mixing (Fusion Flex, Ignite) and flag as non-covered investigational procedures. Update denial reason codes and patient financial responsibility processes. Educate providers that these procedures will result in claim denials and require patient payment discussions prior to treatment.